Severe influenza infections are often characterized as having unique host responses (e.g. 11 early, severe hypercytokinemia). Neuraminidase inhibitors can be effective in controlling the severe 12 symptoms of influenza but are often not administered until late in the infection. Several studies 13 suggest that interferon pre-treatment may offer protection to high risk groups. We test three 14 published ordinary differential equation models of the intrahost immune response during influenza 15 infection to determine which facets of the immune response are most responsible for controlling 16 virus titers over the course of the simulated infection. Each model emphasizes the importance of 17 controlling the infected cell population in order to control viral replication. We also test each model's 18 response to a pre-treatment of interferon before the virus is administered. Our work shows that the 19 structure of current models does not allow for significant response to increased interferon. These 20 results suggest that the current library of available published models of influenza infection does not 21 adequately represent the complex interactions of the virus, interferon, and other aspects of the 22 immune response. Specifically, the method used to model virus-resistant cells may need to be 23 adapted in future work to more realistically represent the immune response to viral infection.
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Influenza A virus (IAV) leads to acute respiratory disease and significant morbidity and 
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Integration was performed with ode23s.
105
We performed two main assessments on the three featured models: a local sensitivity analysis 106 and an interferon pre-treatment study. Sensitivity analysis was performed using a MATLAB package previously published by Nagaraja et al [23] . The Param_var_local.m function performed a local 108 sensitivity analysis on the virus equation in each model to all parameters over a ten day simulation.
109
This sensitivity analysis was additionally used in the calculation of area under the curve (AUC) for 110 each parameter. Parameters which yield the highest AUC over the full ten day simulation are judged 111 to be the most sensitive.
112
Two tests were used to evaluate each model's reaction to simulated interferon treatments. First, 113 five values of the initial level of the IFN present in the system (F0) were tested to assess whether 114 increased initial IFN levels will inhibit viral growth, peak, or clearance. In each case, while the initial 115 condition on the IFN equation changed, all other initial conditions and parameters remain constant.
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Additionally, the amount of time between the initial IFN administration and the start of the infection 117 was varied by delaying the onset of the virus with respect to the IFN. 
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The structure of the Pawelek model is given below in equations 3.1.1: the production and depletion of interferon is expected to be vital to the control of the virus growth 141 throughout the simulation. Over ten days, the parameters with the highest total AUC are the rate of 142 loss of resistance in the epithelial cells (ρ) and the decay rate of infected cells (δ).
143
Figure 2b depicts the model response to changing these two most sensitive parameters 144 concurrently. Colors on the graph correspond to the amount of virus present in the system after ten 145 days, where darker colors indicate more virus present. As δ increases, the infected cells die at a faster 146 rate, and the virus cannot be sustained, leading to a lower virus level at the end of the ten day simulation. As ρ increases, the healthy epithelial cells regenerate at a faster rate, providing a larger 148 pool of cells which may transition to infected cells and produce virus. Thus, as ρ increases, more virus 149 is expected to be present at the end of the simulation. However, the current formulation of the model 150 may overfit the parameters, leading to unexpected trends in the end behavior of the virus.
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Specifically, similar values of ρ and δ result in highly different responses. As more cells become 152 resistant, there is greater feedback to the healthy cell population, allowing for a slight rebound in the 153 target cell population. With more target cells available to become infected, there is an increase in virus 
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A two-dimensional scan of the most sensitive parameters to the clearance rate of the virus from 186 the host is shown in Figure 3b . As expected, when k2 and δ are high, the infected cells die at an 187 increased rate and the virus is completely cleared from the host after ten days. When these parameters 188 are low, however, the infected cell population is sustained and the virus is remains at high levels ten 189 days post-infection. 
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F0 is very low (less than 1), the same initial peak after 12 hours is followed by a long, slow rise in the 
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The other simulations in Figure 5b show that the Pawelek model predicts a negative impact on 252 the host after IFN pre-treatment. With a 2-day pre-treatment (yellow line), the virus trajectory is 253 approximately the same as the nominal model. The initial peak reaches the same magnitude as the 254 nominal model, but the secondary peak is more pronounced. When IFN is given before the virus,
255
there are no infected cells present in the system (which are the only sources of IFN in this model).
256
Thus, the IFN levels will decrease until the virus is introduced on day 2. At that point, the IFN has 257 decreased approximately two orders of magnitude, meaning the initial treatment was not sustained 258 and has had a deleterious effect on the host, as there is less IFN present in the system than under 259 normal circumstances.
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As the delay between IFN and virus lengthens, this effect becomes more pronounced. While the 261 initial virus peak always reaches the same magnitude, the secondary peak, which controls the long-262 term behavior of the system, gets larger with the increased delay. This indicates that the model 263 predicts a chronic influenza infection after significant IFN pre-treatment rather than any 264 improvement in patient outcomes, regardless of the length of time between virus and IFN treatment. 
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Like the Pawelek model, the Saenz model cannot support high levels of IFN without the 285 presence of virus, as only infected cells can produce more IFN. In all simulations, the IFN decays 286 steadily and more rapidly than in the Pawelek simulations in Figure 5 . This is largely due to the 287 differences in the decay rate of IFN between the two models (Pawelek model, d = 1.9 day -1 , Saenz 288 model, d = 6.8 day -1 ). 
295
interferon has no major effect on the system.
296
When the system is tested with a pre-treatment of interferon (Figure 7b ), there is little change in 297 the behavior of the virus. The entire system shifts horizontally with the time delay, but the overall 298 behavior of the model does not change. Like in previous models, without a starting virus population,
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the system cannot sustain the initial concentration of IFN. When the virus is finally introduced, the 300 IFN level has essentially fallen to zero, making any impact from the pre-treatment negligible. 
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All models must make some simplifying assumptions, and thus, no models are fully accurate in 316 their representation of the host response to IFN treatment. While these models had been analyzed in 317 previous reviews [28], previous work had only shown how these models respond to knockouts of 318 various immune components. Here, we perform a complementary study to test early administration 319 as well as increased initial levels of IFN to determine if altering IFN levels can improve patient 320 outcomes. Of the three models studied, only one showed significant impact after early IFN treatment.
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The Saenz model predicts a lower viral peak with increased initial interferon levels and a monotonic 
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While the models presented do capture many aspects of the immune response to IAV infection,
357
we cannot be certain that IFN pre-treatment is accurately portrayed in these models without more 358 experimental data with which to train the models. An experiment in which hosts are treated with 359 interferon days before the virus is administered is vital for validating the models' behavior. These 360 experiments will also inform future treatment plans for appropriate timing and magnitude of IFN 361 administration in virus-infected hosts. 
